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C
 
ell death by apoptosis is a tightly regulated physiologi-
cal process that enables the elimination of unwanted
cells. It is crucial for embryonic development and the
maintenance of tissue homeostasis, but also for defense
against certain infectious diseases and cancer.
Apoptosis can be triggered from outside the cell, gener-
ally after cell–cell contact, by a family of transmembrane
proteins called death receptors, which belong to the TNF
 
family of receptors. Six human death receptors (Fas [Apo-1,
 
CD95], TNFR-1, TRAMP [WSL-1/Apo-3/DR-3/LARD],
TNF-related apoptosis-inducing ligand [TRAIL]R-1 [DR-
 
4], TRAILR-2 [DR-5, TRICK-2,
 
 
 
KILLER], and DR-6)
have been identified to date (1, 2), and all contain a cyto-
plasmic sequence named “death domain” (DD) that cou-
ples each receptor to caspase cascades essential for the in-
duction of apoptosis. The best studied signaling pathway is
the one triggered by binding of Fas ligand (L) to Fas. Sche-
matically, multimerization or clustering of Fas upon bind-
ing of the membrane-bound form of FasL recruits the bi-
partite molecule FADD (Fas-associated death domain,
 
composed of an NH
 
2
 
-terminal death effector domain
[DED] and a COOH-terminal DD). FADD binds to Fas
 
(via homophilic DD–DD interactions) and recruits the
upstream DED-containing caspase-8 (and probably cas-
pase-10) to the receptor via homophilic DED–DED inter-
actions. Caspase-8 (or -10) within this newly formed
death-inducing signaling complex then proteolytically au-
toactivates itself and initiates apoptosis by subsequent cleav-
age of downstream effector caspases (caspase-3, -6, and -7)
(Fig. 1).
Fas signaling is known to be implicated in peripheral de-
letion of autoimmune cells, activation-induced T cell
death, and CTL-mediated target cell death (for review see
references 1 and 3). To avoid inappropriate cell death and
disease, however, death receptor signals must be tightly
controlled. It is known that death receptor apoptosis can be
inhibited at different points: at the receptor level (by recep-
tor endocytosis, soluble ligands, and/or decoy receptors),
during signal transduction, and at the effector stage (e.g.,
caspase inhibitors CrmA, p35, and inhibitor of apoptosis
proteins [IAPs]). Recently, we identified a new family of
viral inhibitors of death receptor–mediated cell death
 
named vFLIPs (FADD-like IL1
 
b
 
–converting enzyme
[FLICE]/caspase-8–inhibitory proteins) that are found in
several herpesviruses (including oncogenic human herpes-
 
virus 8/Kaposi’s sarcoma–associated herpesvirus and
 
molluscipox virus) and inhibit DED–DED interactions
between FADD and caspase-8 and -10 (4). Cellular homo-
logues of vFLIPs were subsequently identified by us and
others (cFLIPs; aliases Casper, iFLICE, FLAME-1, CASH,
CLARP, MRIT, and usurpin) and shown to structurally
resemble caspase-8, except that they lack proteolytic activ-
ity (5, 6). Their inhibition of caspase-8 activation renders
cells resistant to apoptotic signals transmitted by Fas and all
other death receptors known to date (Fig. 1).
Although the exact physiological function of cFLIP has
yet to be completely elucidated, a role in disease was rap-
idly suspected. Indeed, several viruses, some of which are
oncogenic, and human malignant melanomas express high
levels of FLIP (4, 5). It was therefore postulated that virally
infected cells and tumor cells may thereby acquire a certain
degree of immune privilege by becoming resistant to FasL
and perhaps other death ligands. The in vivo relevance of
this hypothesis has since remained open and uncertain,
however, as CTLs can lyse their targets through both Fas-
and perforin-dependent pathways, and FLIP has only been
shown to inhibit the former, at least in vitro (7).
 
In this issue, papers by Medema et al. (8) and Djerbi et al.
(9) have clarified this issue. Both clearly demonstrate in dif-
ferent tumor models that in vivo expression of FLIP con-
fers an advantage to tumors within an immunocompetent
setting. In addition, they show that induction of tumor cell
death by death receptor triggering is a more important
mechanism of defense against tumors than had been sus-
pected to date.
Djerbi et al. (9) generated mouse A20 lymphoma trans-
fectants that stably overexpress viral FLIP from HHV8.
These vFLIP-A20 cells, when compared with mock-trans-
fected A20 cells, were shown to be resistant to Fas-medi-
ated apoptosis by inhibition of caspase-8 activation but also
showed decreased caspase-9 and -3 activation after trigger-
ing by FasL. Additionally, when grown in the continuous
presence of death stimuli (agonistic anti-Fas antibody),
vFLIP selectively allowed A20 cells to grow clonally.
When tested in vivo using syngeneic (BALB/c) or semial-
logeneic (BALB/c 
 
3
 
 C57BL/6) F1 recipients injected sub-
cutaneously, both the frequency of tumor appearance and
the time to tumor appearance were drastically higher for
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vFLIP-A20 cells as compared with mock-A20 cells. De-
pending on the vFLIP-A20 clone tested, in syngeneic mice
vFLIP-A20 cells induced tumors in roughly 90% of mice
versus 32% for mock-A20 cells. Similarly, in semiallogeneic
mice, vFLIP-A20 cells induced tumors in roughly 65–80%
of mice, depending on the clone used, versus 17% for
mock-A20 cells. Further experiments revealed that this dif-
ference is most likely due to T cell immune escape con-
ferred by vFLIP, as tumor establishment and growth of
transfected and mock A20 cells was virtually identical in
SCID mice.
The experimental approach used by Medema et al. (8) is
quite different to that of Djerbi et al. (9) but provides us
with exciting complementary information. These authors
have assessed the effect of cellular FLIP in tumorigenesis
and immune escape using stable cFLIP transfectants of two
distinct cell lines: (a) a Fas-transfected Moloney murine
leukemia virus–induced lymphoma (MBL2-Fas) and (b) a
mouse embryo cell tumor line (AR6) generated by trans-
fection of adenovirus type 5 E1A and mutant EJ-
 
ras
 
 onco-
genes. The latter express low but detectable levels of Fas,
whereas the former express high levels of Fas. Independent
cFLIP transfectant clones from both the MBL2-Fas and
AR6 cell lines were shown to be resistant to Fas-mediated
cell death in vitro as compared with mock-transfected
counterparts. In agreement with previous results (7), these
FLIP transfectants are, however, sensitive to CTL-induced
apoptosis in vitro, the perforin pathway being able to in-
duce target cell apoptosis despite caspase-8 (and -10) inhi-
bition by FLIP.
When these cell lines are injected in vivo, similar to the
results of Djerbi et al. (9), Medema et al. (8) show that
transfectants expressing little or no FLIPs are rejected in the
majority of mice, whereas injection of the same number of
cells expressing high amounts of FLIP consistently resulted
in tumor development. When injected into nude mice,
both cell types result in tumors that grow equally fast no
matter how much FLIP they express. Thus, FLIP offers sig-
nificant protection from the in vivo immune response to
these tumors, and protection is not limited to tumors with
high Fas expression (MBL2-Fas). Additionally and interest-
ingly, when the same experiments were performed in per-
forin-deficient mice with the AR6 cell line, AR6-FLIP tu-
mors grew nearly as efficiently as in wild-type mice,
suggesting that elimination of this tumor by the immune
system depends almost exclusively on the Fas pathway. Last
but not least, when the rare tumors that had developed in
mice injected with MBL2-Fas cells expressing low amounts
of FLIP were analyzed in vitro, they were shown to have
become Fas resistant and high expressors of FLIP. Thus, tu-
mor cells appear to be selected in vivo for elevated FLIP
expression, most likely due to selective pressure by the im-
mune system.
The novel and complementary experimental data pre-
Figure 1. Fas (death receptor) signaling pathway and its inhibition. Fas
(or other death receptor) signaling is triggered on target cells by receptor
tri(multi)merization subsequent to FasL (or other appropriate trimeric
death ligand). Subsequent recruitment of FADD (by DD–DD interac-
tion) and procaspase-8 or -10 (by DED–DED interaction) leads to up-
stream caspase (caspase-8 or -10) autoactivation, which initiates apoptosis
by subsequent cleavage of downstream effector caspases (caspase-3, -6,
and -7). Death receptor apoptosis can be inhibited at different points
(red): at the receptor level, e.g., by soluble ligands (a) and/or decoy re-
ceptors; (b) by receptor internalization, e.g., by adenovirus E3-10.4/
14.5K (c); by downregulation of receptor expression, e.g., by oncogenic
H-Ras (c); during signal transduction by FLIPs (d, e, and f); and at the ef-
fector stage (by caspase inhibitors, e.g., cowpox-encoded CrmA, bacu-
lovirus p35, adenovirus 14.7, and/or IAPs [g]).
Figure 2. Inhibition of death receptor signaling as a mechanism of tu-
mor immune escape. CTLs use two major pathways (perforin/granzyme
granule exocytosis and Fas) to induce target cell (tumor) death by apopto-
sis after TCR–MHC–peptide complex engagement. By downregulating
Fas surface expression or by producing FLIP, tumor cells can escape im-
mune destruction mediated by the Fas death receptor signaling pathway
in vivo, despite the persistence of a functional perforin/granzyme granule
exocytosis pathway.
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sented in the papers by Medema et al. and Djerbi et al.
bring about two important new pieces of information. The
first is that Fas-mediated apoptosis is a more important
mechanism of defense against tumors than had been sus-
pected to date. The second is that FLIP expression by tu-
mors is a significant and novel mechanism of immune es-
cape from T cell immunity in vivo (Fig. 2). This may
appear to be a surprise, as FLIP does not affect perforin-
mediated lysis by CTLs in vitro. However, as suggested by
Medema et al. (8), this discrepancy may be due to limita-
tions of classical in vitro cytolysis assays that may not reflect
the situation occurring in the tumor microenvironment as
accurately as currently conceived. In line with this observa-
tion, recent evidence suggests that to trigger the release of
perforin/granzyme B from cytoplasmic granules, stronger
and more persistent TCR signals may be required than for
the release of FasL (Fig. 2). Furthermore, whereas partial
agonistic MHC peptides are capable of eliciting FasL but
not perforin cytotoxicity, strong signals from fully agonistic
MHC peptides trigger both pathways (10). Consequently,
in vivo CTL recognition of tumor cells as “nonself” may
be inefficient, leading to preferential activation of FasL and
leaving the perforin pathway virtually unimplicated.
In humans, FLIP has been shown to be overexpressed in
melanomas, tumors that elicit T cell responses including
the generation of melanoma-directed CTLs. Despite evi-
dence for the in vivo generation of such CTLs, spontane-
ous regression of malignant melanoma only rarely occurs.
The mechanisms thought to be responsible for this tumor
immune escape to date include the expression of local in-
hibitory factors by tumor cells, such as transforming growth
factor 
 
b
 
, IL-10, and FasL, deficient antigen processing by
tumor cells or loss of MHC expression, the lack of immu-
nogenicity and costimulation for CTL activation, and de-
fective lymphocyte homing to tumors. In certain tumor
cell types, downregulation of Fas by oncogenic Ras is also
observed, thereby rendering tumor cells resistant to FasL
(11). Functionally, this has the same effect as overexpres-
sion of FLIP, which can now be added to the above list
with reasonable confidence. Although not reported to date,
FLIP upregulation may well be implicated in the pathogen-
esis of tumors other than melanomas.
Current attempts to improve cancer survival depend es-
sentially on early diagnosis and the development of new
treatment modalities, one of the most promising being im-
munotherapy. Given the new findings described herein,
strategies to inhibit FLIP expression and/or FLIP-mediated
inhibition of death receptor signaling may prove to be a
useful complementary approach to the treatment of cancer.
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